Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA lifts hold on Pluristem trial; shares rise

This article was originally published in Clinica

Executive Summary

Shares of Pluristem Therapeutics rose as much as 8.7% on 16 September after the company revealed the US FDA had lifted its clinical hold on the firm's Phase II study of experimental placenta-based cell therapy, PLX-PAD, in intermittent claudication (IC) – with the agency declaring the firm had satisfactorily addressed all issues raised by regulators.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts